BACKGROUND: Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients. This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients. PATIENTS AND METHODS: Fifty-one patients were included. Patients had a median number of 2 prior chemotherapeutic regimens for MBC (range 0-7) consisting of anthracyclines and taxanes: 26 patients (51%); anthracyclines: nine patients (17.6%); taxanes: seven patients (13.7%); others: five patients (9.8%). Bendamustine was administered four weekly at a dose of 120 mg/m(2) on days 1 and 2. RESULTS: Fifty patients were assessable. Of total, 200 courses were administered. We observed no complete response (CR); 10 patients [20%; 95% confidence interval (CI): 10.0% to 33.7%] achieved a partial response (PR), 14 patients (28%) remained stable for at least 6 months resulting in a clinical benefit rate (CR + PR + stable disease) of 48% (95% CI: 33.7%to 52.6%). Median time to progression was 3.4 months (range 1-51.1). The median duration of remission was 6.6 months (range 1.8-48.7). The treatment was well tolerated with mainly hematologic toxic effects. CONCLUSION: Single-agent bendamustine is an active treatment in patients with MBC independent of the previous treatment. The low toxicity profile favors its use as a single agent.
BACKGROUND:Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients. This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients. PATIENTS AND METHODS: Fifty-one patients were included. Patients had a median number of 2 prior chemotherapeutic regimens for MBC (range 0-7) consisting of anthracyclines and taxanes: 26 patients (51%); anthracyclines: nine patients (17.6%); taxanes: seven patients (13.7%); others: five patients (9.8%). Bendamustine was administered four weekly at a dose of 120 mg/m(2) on days 1 and 2. RESULTS: Fifty patients were assessable. Of total, 200 courses were administered. We observed no complete response (CR); 10 patients [20%; 95% confidence interval (CI): 10.0% to 33.7%] achieved a partial response (PR), 14 patients (28%) remained stable for at least 6 months resulting in a clinical benefit rate (CR + PR + stable disease) of 48% (95% CI: 33.7%to 52.6%). Median time to progression was 3.4 months (range 1-51.1). The median duration of remission was 6.6 months (range 1.8-48.7). The treatment was well tolerated with mainly hematologic toxic effects. CONCLUSION: Single-agent bendamustine is an active treatment in patients with MBC independent of the previous treatment. The low toxicity profile favors its use as a single agent.
Authors: Rachel M Layman; Amy S Ruppert; Melinda Lynn; Ewa Mrozek; Bhuvaneswari Ramaswamy; Maryam B Lustberg; Robert Wesolowski; Susan Ottman; Sarah Carothers; Anissa Bingman; Raquel Reinbolt; Eric H Kraut; Charles L Shapiro Journal: Cancer Chemother Pharmacol Date: 2013-02-21 Impact factor: 3.333
Authors: Jacob D Soumerai; Andrew D Zelenetz; Craig H Moskowitz; M Lia Palomba; Paul A Hamlin; Ariela Noy; David J Straus; Alison J Moskowitz; Anas Younes; Matthew J Matasar; Steven M Horwitz; Carol S Portlock; Jason A Konner; Mrinal M Gounder; David M Hyman; Martin H Voss; Matthew G Fury; Devika Gajria; Richard D Carvajal; Alan L Ho; Jan H Beumer; Brian Kiesel; Zhigang Zhang; Alice Chen; Richard F Little; Christine Jarjies; Thu O Dang; Fallon France; Nishant Mishra; John F Gerecitano Journal: Clin Cancer Res Date: 2017-03-17 Impact factor: 12.531
Authors: Sibylle Loibl; Gabriele Doering; Lothar Müller; Albert Grote-Metke; Roberto Müller; Oliver Tomé; Wolfgang Wiest; Andrea Maisch; Valentina Nekljudova; Gunter von Minckwitz Journal: Breast Care (Basel) Date: 2011-12-15 Impact factor: 2.860
Authors: Gabriel Rinnerthaler; Simon Peter Gampenrieder; Andreas Petzer; Michael Hubalek; Edgar Petru; Margit Sandholzer; Johannes Andel; Marija Balic; Thomas Melchardt; Cornelia Hauser-Kronberger; Clemens A Schmitt; Hanno Ulmer; Richard Greil Journal: Ther Adv Med Oncol Date: 2021-10-19 Impact factor: 8.168